Janus Henderson Global Life Sciences Fund Class S (JFNSX)

57.64
Net Asset Value
+0.03%
1 Day
+7.92%
Year-to-Date
Overall Morningstar Rating
Health
Style or Category
No Load
Sales Expenses
1.17%
Expense Ratio
Above Average
Morningstar Risk Rating™
Investment Objective The investment seeks long-term growth of capital. The fund pursues its investment objective by investing- under normal circumstances- at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that the portfolio managers believe have a life science orientation. In the fund's pursuit of companies with a life science orientation- the fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the "life sciences" sector.

Performance

1 month+2.14% 3 years+1.90%
3 months+2.42% 5 years+16.18%
1 year+15.49% Since inception+18.05%
Data through --

Peer Comparisonvs. Health

 JFNSXCategory
Performance 5-yr return+16.18%+14.29%
Expense ratio1.17%1.29%
Risk 5 year sharpe ratio0.980.89
Net assets$3.6B$2.9B
Average market cap$18.1B$9.8B
Average P/E26.622.0
Portfolio turnover38%38%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyJanus Henderson
Fund manager & tenureAndrew Acker / 11 Years
Minimal initial investment$2,500.00
Minimum IRA investment--

Holdings

U.S. stock78.18%
International stock17.20%
Fixed income2.53%
Cash1.62%
Other0.47%
Top 5 Sectors
Portfolio weighting
Healthcare 94.74%
Consumer service 3.23%
Consumer goods 0.79%
Business service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
-- 3.42%
LLY Eli Lilly and Co2.69%
SHPG Shire2.66%
-- 2.62%
HUM Humana Inc2.42%
BSX Boston Scientific Corp2.28%
CELG Celgene2.24%
NKTR Nektar Therapeutics2.19%
ANTM WellPoint2.09%
BIIB Biogen2.08%